RPTX – repare therapeutics inc. - common shares (US:NASDAQ)
Stock Stats
News
Repare Therapeutics Inc. (NASDAQ: RPTX) had its "market perform" rating re-affirmed by analysts at Lifesci Capital.
Repare Therapeutics eyes Phase III cancer study after Mythic trial success [Yahoo! Finance]
Repare Therapeutics Inc. (NASDAQ: RPTX) had its price target lowered by analysts at Stifel Nicolaus from $9.00 to $4.00. They now have a "buy" rating on the stock.
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial [Yahoo! Finance]
Form 8-K Repare Therapeutics Inc. For: Dec 12
Form SC 13G/A Repare Therapeutics Inc. Filed by: Redmile Group, LLC
Form SC 13G/A Repare Therapeutics Inc. Filed by: Blue Owl Capital Holdings LP
Form SC 13G/A Repare Therapeutics Inc. Filed by: Deep Track Capital, LP
Form 424B5 Repare Therapeutics Inc.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.